Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rhythm Pharmaceuticals ( (RYTM) ) has shared an update.
On July 9, 2025, Rhythm Pharmaceuticals announced positive topline results from its Phase 2 trial of bivamelagon, an investigational oral MC4R agonist, in patients with acquired hypothalamic obesity. The trial demonstrated statistically significant and clinically meaningful reductions in BMI over 14 weeks, with bivamelagon achieving reductions comparable to those seen with setmelanotide in similar patient populations. The trial also showed meaningful reductions in hunger scores and consistent safety and tolerability results. Rhythm plans to engage with regulatory authorities to advance bivamelagon to a Phase 3 trial, aiming to establish it as a treatment for acquired hypothalamic obesity.
The most recent analyst rating on (RYTM) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.
Spark’s Take on RYTM Stock
According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.
Rhythm Pharmaceuticals’ overall stock score reflects strong technical momentum and positive earnings call insights, which are tempered by financial performance challenges and valuation concerns. The company’s strategic advancements and robust pipeline position it well for future growth, but profitability remains a key challenge.
To see Spark’s full report on RYTM stock, click here.
More about Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on transforming the lives of patients with rare neuroendocrine diseases. Its lead asset, IMCIVREE® (setmelanotide), an MC4R agonist, is approved for treating hyperphagia and severe obesity in patients with specific genetic conditions. Rhythm is also developing investigational MC4R agonists like bivamelagon and RM-718, and a suite of small molecules for congenital hyperinsulinism.
Average Trading Volume: 638,333
Technical Sentiment Signal: Buy
Current Market Cap: $4.22B
For a thorough assessment of RYTM stock, go to TipRanks’ Stock Analysis page.